| Drug Name | ZOFRAN (Ondansetron) |
|---|---|
| Drug Class |
Anti-emetic
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Oncology
|
| Risk |
Direct Healthcare Professional Communication on the risk of birth defects from the recently published epidemiological studies for Zofran® (Ondansetron) Risk of developing abnormal changes in the electrical activity of the heart ZOFRAN® (ondansetron) - updated information on posology for intravenous use |
| Dear Healthcare provider letter DHPC |
|